Xeris Biopharma (NASDAQ:XERS) Trading Up 8.2% – Still a Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares were up 8.2% during mid-day trading on Wednesday . The company traded as high as $3.44 and last traded at $3.44. Approximately 783,646 shares traded hands during trading, a decline of 54% from the average daily volume of 1,704,671 shares. The stock had previously closed at $3.18.

Wall Street Analyst Weigh In

XERS has been the subject of a number of analyst reports. HC Wainwright boosted their price target on Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a research report on Monday, November 11th. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a research report on Monday, November 11th.

Xeris Biopharma Price Performance

The business has a 50 day moving average price of $3.04 and a 200 day moving average price of $2.60. The firm has a market capitalization of $512.84 million, a P/E ratio of -7.53 and a beta of 2.70.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Xeris Biopharma by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after acquiring an additional 519,897 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Xeris Biopharma by 2.9% during the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after buying an additional 93,091 shares in the last quarter. Rosalind Advisors Inc. lifted its holdings in Xeris Biopharma by 10.6% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company’s stock worth $7,020,000 after buying an additional 300,000 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Xeris Biopharma by 33.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock worth $3,041,000 after buying an additional 342,300 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in Xeris Biopharma by 4.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,193,080 shares of the company’s stock worth $2,684,000 after buying an additional 52,074 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.